Stryker Says It's Not Chasing Boston Scientific
Executive Summary
Rumors of a potential Stryker-Boston Scientific coupling have been quashed after the orthopedics player officially stated it is not in discussions with the cardiology company.
You may also be interested in...
Stryker Takes A Shine To Photonics Firm Invuity
Just weeks after inking a billion-dollar acquisition of K2M, Stryker has announced a $190m deal to acquire photonics firm Invuity. Under the terms of the agreement, a subsidiary of Stryker will purchase all outstanding shares of Invuity for $7.40 per share in cash.
9 + 11 = Possible 3: Can A Stryker-Boston Scientific Combo Work?
Unconfirmed rumors of Stryker having approached Boston Scientific about a takeover bid raised eyebrows all around, not least because the move – reported on June 11 – was so unexpected. But would a combination of the medtech industry's No. 9 and No. 11, to create a broad-scale portfolio with very little product overlap, make strategic sense? Reactions have been mixed.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.